Add
APPA to Portfolio
Set Alert
Email to a
Friend
| |||
|
|
Quotes & Info
|
| APPA > SEC Filings for APPA > Form 8-K on 17-Oct-2012 | All Recent SEC Filings |
17-Oct-2012
Other Events, Financial Statements and Exhibits
On October 16, 2012, A.P. Pharma, Inc. (the "Company") announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's resubmission of its New Drug Application (NDA) for its lead product candidate, APF530, for the prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). The FDA has set a Prescription Drug User Fee Act (PDUFA) action date of March 27, 2013.
(d) Exhibits.
Exhibit No. Document Description
99.1 Press Release issued on October 16, 2012
|
|